Hemab Therapeutics Secures $346.7M IPO and FDA Breakthrough for Sutacimig
Hemab Therapeutics completed an upsized IPO in May 2026, raising $346.7 million to list on Nasdaq and held $163.5 million cash at quarter end, extending runway into 2029. Sutacimig received FDA Breakthrough Therapy Designation for Glanzmann thrombasthenia, and Hemab plans to start a Phase 3 pivotal trial in H2 2026.
1. Upsized IPO Raises $346.7 Million
In May 2026 Hemab sold 19.26 million shares at $18.00 per share including full underwriter exercise, raising gross proceeds of $346.7 million and listing on Nasdaq. As of March 31, cash, cash equivalents, and marketable securities totaled $163.5 million, providing runway into 2029 along with net IPO proceeds.
2. FDA Breakthrough Therapy Designation for Sutacimig
The FDA granted Breakthrough Therapy Designation to sutacimig for Glanzmann thrombasthenia following completion of Part B in the Phase 1/2 trial. Hemab is preparing to initiate a Phase 3 pivotal trial in the second half of 2026 to evaluate safety and efficacy in patients.
3. Ongoing Clinical Trials for Coagulation Disorders
Sutacimig is also in a Phase 2 trial for Factor VII deficiency with data expected in late 2026 or early 2027. HMB-002, a monovalent antibody for Von Willebrand Disease, is in Phase 1/2, and multiple preclinical assets target additional bleeding and thrombotic disorders.
4. First Quarter 2026 Financial Performance
Research and development expenses rose to $19.5 million from $14.1 million year-over-year, while general and administrative costs increased to $4.2 million from $2.5 million due to IPO preparations. Net loss for Q1 2026 was $22.7 million, or $23.98 per share, versus $15.3 million, or $16.18 per share, in Q1 2025.